Abstract
Inhibition of sclerostin in the management of osteoporosis: results of a phase 2 clinical trial meet expectations.
Full Text
Sign-in/Register to access full text options
Published version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have